<DOC>
	<DOCNO>NCT01425723</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety rFIXFc participant hemophillia B . The secondary objective study evaluate efficacy rFIXFc prevention treatment bleed episode .</brief_summary>
	<brief_title>Long-Term Safety Efficacy rFIXFc Prevention Treatment Bleeding Episodes Previously Treated Participants With Hemophilia B</brief_title>
	<detailed_description>Participants follow either prophylaxis on-demand regimen . The start dose study determine clinical profile patient precede study , B-LONG 998HB102 ( NCT01027364 ) Kids B-LONG study 9HB02PED ( NCT01440946 )</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Key Subjects complete study 998HB102 ( NCT01027364 ) 9HB02PED ( NCT01440946 ) study rFIXFc Ability understand purpose &amp; risk study provide sign date informed consent . Key Hightiter inhibitor ( &gt; /=5.00 BU/mL ) NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>B-LONG</keyword>
	<keyword>B-YOND</keyword>
	<keyword>B-LONG Extension</keyword>
	<keyword>rFIXFc</keyword>
	<keyword>Severe Hemophilia B</keyword>
</DOC>